The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

formerly of Vertex Pharmaceuticals' (Cambridge, MA) HIV protease inhibitor program. As yet, no details of Althexis targets have been forthcoming. Breaking off the attachment Since bacterial ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research ...

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the ...